Atherosclerosis Therapeutics Market Size 2024-2028 

The atherosclerosis therapeutics market size is estimated to grow by USD 2.66 billion at a CAGR of 4.5% between 2024 and 2028. Atherosclerosis, a condition characterized by the buildup of plaque in the arterial walls, poses a significant health risk due to increasing risk factors such as an unhealthy diet, sedentary lifestyle, and smoking. Advanced diagnostic methods, including ultrasounds, CT scans, and MRI, are now widely available to detect atherosclerosis in its early stages, allowing for timely intervention and prevention of complications. Moreover, the prevalence of hypercholesterolemia, a condition marked by high levels of cholesterol in the blood, is on the rise, further increasing the importance of regular screenings and proactive measures to manage this condition and reduce the risk of atherosclerosis. By staying informed about these developments and taking steps to maintain a healthy lifestyle, individuals can significantly reduce their risk of developing atherosclerosis and its associated complications.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

Atherosclerosis is a chronic condition characterized by the buildup of plaque, which is made up of fatty materials, cholesterol, cellular waste products, calcium, fibrin, and other substances, in the arteries. This condition can lead to various health issues, including vascular illnesses in the extremities and organs such as the heart, brain, and lungs. The market caters to the development and distribution of medications used to manage this condition. Antiplatelet medications, cholesterol lowering medications, beta blocker medications, and ACE inhibitor medications are among the commonly used therapeutics. Clinical trials are ongoing to explore new treatment options, including the use of statin treatment to manage chronic endothelial inflammation and maintain hemostatic balance. The inflammatory response and vasomotor tone are key targets for new therapeutic interventions. The market is driven by the increasing prevalence of the condition, particularly among an aging population and those with unhealthy lifestyles. The SARS CoV2 infection has also highlighted the importance of managing vascular illnesses, as these conditions increase the risk of severe complications. Health-conscious consumers are also driving demand for new and effective treatments. However, the complex nature of atherosclerosis and the potential for side effects limit the development of new therapeutics. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

Increasing risk factors for atherosclerosis is notably driving market growth. Atherosclerosis is a complex disease characterized by the inflammation of endothelial cells lining the arterial walls, leading to plaque formation and disruption of hemostatic balance. Risk factors such as sedentary lifestyles, high blood pressure, high cholesterol, obesity, and high alcohol consumption contribute to the development and progression of atherosclerosis. These factors trigger an inflammatory response, resulting in vasomotor tone imbalance, cytokine storm, and artery blockages.

Furthermore, thrombotic problems such as ischemia, stroke, and myocardial infarction are common complications of advanced atherosclerosis. The prevalence of atherosclerosis is increasing due to the rising consumption of energy-dense foods and decreasing infrastructure for healthcare services. Treatment options for atherosclerosis include statins, fibrates, and thrombotic interventions. Statin treatment inhibits the production of cholesterol, while fibrates enhance the removal of lipids from the bloodstream. However, these treatments do not address the underlying inflammatory processes, and new therapeutic approaches are being explored to target these mechanisms effectively. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

Identification of new pathogenic targets is the key trend in the market. Atherosclerosis is a chronic inflammatory condition characterized by the buildup of plaque in the arterial walls. The complex etiology of atherosclerosis involves several factors, including sedentary lifestyles, high blood pressure, high cholesterol, obesity, and high alcohol consumption. One potential contributor to atherosclerosis is infection by Chlamydia pneumoniae (C. pneumoniae), which can trigger an inflammatory response in the endothelial cells lining the arterial walls. This response results in the production of cytokines, such as interferons (IFN) and interleukins (IL), and growth factors, leading to the activation of smooth muscle cells and macrophages.

Furthermore, the subsequent formation of atheroma involves the deposition of lipids, calcium, and other substances in the arterial wall, leading to artery blockages and increased risk of ischemic heart disease, stroke, and arterial thrombosis. Statin treatment, fibrates, and lifestyle modifications are common therapeutic approaches to manage atherosclerosis and its complications. The prevalence of atherosclerosis is high, particularly in developed countries, necessitating significant investment in healthcare services and infrastructure to diagnose and treat this condition. Energy dense foods and processed foods also contribute to the development of atherosclerosis, making dietary modifications an essential component of preventive measures. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenge

Side-effects associated with atherosclerosis therapeutics is the major challenge that affects the growth of the market. Atherosclerosis, characterized by the inflammation of endothelial cells lining the arterial walls, disturbs the hemostatic balance, leading to an inflammatory response and vasomotor tone imbalance. This condition, prevalent in individuals with sedentary lifestyles, high blood pressure, high cholesterol, obesity, and high alcohol consumption, results in plaque formation and subsequent artery blockages. Thrombotic problems, such as ischemia, stroke, and myocardial infarction, ensue due to plaque rupture and subsequent clot formation. The global market encompasses small molecules, including statins, ACE inhibitors, beta-blockers, antiplatelet agents, calcium channel blockers, and nitrates. Statins, or cholesterol-lowering drugs, are primary medications for atherosclerosis treatment. For instance, ZOCOR (simvastatin) is a statin used as an adjunct to diet and exercise, acting by lowering LDL cholesterol levels in the blood.

Furthermore, high LDL cholesterol is a significant risk factor for atherosclerosis, making ZOCOR an essential medication for preventing plaque formation. However, statins may cause potential side effects, necessitating the development of alternative therapeutic approaches. Healthcare services and infrastructure continue to evolve, leading to increased diagnostic rates for atherosclerosis and associated cardiovascular diseases (CVDs), such as ischemic heart disease. The market is expanding, with several players offering various treatments, including statins, fibrates, and polymer-based therapies. Energy-dense foods and unhealthy lifestyles contribute to the rising prevalence of atherosclerosis, necessitating the development of effective and safe therapeutic interventions. Hence, the above factors will impede the growth of the market during the forecast period

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Amgen Inc. - The company offers atherosclerosis therapeutics such as Repatha (evolocumab) and optimized statin therapy.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Amgen Inc.
• AstraZeneca Plc
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Ionis Pharmaceuticals Inc.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

By Product 

The market share growth by the Small molecules segment will be significant during the forecast period. the treatment of Atherosclerosis, a chronic condition characterized by the buildup of plaque composed of fatty materials, cholesterol, cellular waste products, calcium, fibrin, and other substances in the arterial walls. This condition can lead to inflammation in the body organs, affecting the extremities, and increasing the risk of cardiovascular diseases, particularly in the geriatric population.

Get a glance at the market share of various regions Download the PDF Sample

The small molecules segment showed a gradual increase in the market share of USD 8.70 billion in 2018. Antiplatelet medications and cholesterol-lowering medications are commonly prescribed to manage Atherosclerosis. Cholesterol-lowering medications include statins, ezetimibe, and bile acid sequestrants, while beta blocker medications and ACE inhibitor medications are used to manage blood pressure and reduce inflammation. Clinical trials are ongoing to develop new treatments, including vaccinations and drugs that target specific proteins involved in the disease process. Health-conscious consumers are increasingly seeking out these medications through various channels, including hospitals, pharmacies, online providers, and drug stores. Poor eating habits and unhealthy lifestyles are major contributors to Atherosclerosis, making carbohydrate-based foods and vaccinations important preventative measures. The ongoing COVID-19 pandemic has highlighted the importance of vascular health, as SARS CoV2 infection can worsen chronic endothelial inflammation and increase the risk of cardiovascular events. The market for Atherosclerosis drugs is expected to grow significantly due to the increasing prevalence of the disease and the development of new treatments.

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market caters to the demand for medications used in the treatment of Atherosclerosis, a chronic condition characterized by the buildup of plaque made up of fatty materials, cholesterol, cellular waste products, calcium, and fibrin in the arteries. This condition can affect various body organs and extremities, leading to inflammation and potential damage to the heart, brain, and lungs. Antiplatelet medications and cholesterol-lowering medications are commonly prescribed to manage this condition. Beta blocker medications and ACE inhibitor medications are also used to control symptoms and prevent complications. Clinical trials are ongoing to develop new treatments, and health-conscious consumers are increasingly seeking preventative measures, including dietary modifications, such as reducing consumption of carbohydrate-based foods and poor eating habits, as well as vaccinations and lifestyle changes. The geriatric population and those with cardiovascular diseases are primary targets for these treatments. The market for Atherosclerosis drugs is expanding due to the increasing prevalence of the condition, driven by factors such as unhealthy lifestyles and medical tourism. These medications are available at hospitals, pharmacies, online providers, and drug stores. The ongoing SARS CoV2 infection and its impact on vascular illness have further emphasized the importance of managing chronic endothelial inflammation.

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Product Outlook
  • Small molecules
  • Biologics

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Chile
    • Argentina
    • Brazil

You may also interested in the below market reports

• Cardiovascular Therapeutics Market: Cardiovascular Therapeutics Market Analysis Asia, North America, Europe, Rest of World (ROW) - US, Mexico, Russia, China, India - Size and Forecast

• Stroke Therapeutics Market: Stroke Therapeutics Market by Type and Geography - Forecast and Analysis

• Acute Ischemic Stroke Therapeutics Market: Acute Ischemic Stroke Therapeutics Market by Type, Distribution Channel, and Geography - Forecast and Analysis

Market Analyst Overview

Atherosclerosis, a chronic condition characterized by the buildup of plaque made up of fatty materials, cholesterol, cellular waste products, calcium, fibrin, and other substances in the arteries, is a leading cause of cardiovascular diseases. The market is witnessing significant growth due to the increasing prevalence of this condition, particularly in the geriatric population and those with poor eating habits and unhealthy lifestyles. Antiplatelet medications, cholesterol-lowering medications, and beta blocker medications are commonly used to manage atherosclerosis. Clinical trials are ongoing to develop new treatments, including ACE inhibitor medications, which are effective in reducing the risk of heart attacks and strokes.

Furthermore, the market is driven by the rising number of health conscious consumers, medical tourism, e-commerce, and the availability of various delivery methods, such as oral and injectable. The market is also influenced by the increasing prevalence of vascular illnesses, chronic endothelial inflammation, and the impact of lung diseases like SARS CoV2 infection on the cardiovascular system. Key players in the market include hospitals, pharmacies, online providers, drug stores, and e-commerce platforms. The market is expected to grow further due to the increasing demand for cholesterol-lowering medications and ACE inhibitors. However, the high cost of these medications and the availability of alternative treatments like vaccinations and lifestyle modifications may limit market growth.

Download PDF Sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies